New from the @IrisJaffeLab! 🙌
Ponatinib, a potent anticancer therapy, activates #EndothelialCells and platelets, driving plaque inflammation and death from MI and stroke in mice, mirroring clinical cardiotoxicities in patients with cancer. | @CircAHA
🔗 https://t.co/oBKhd0PJxs
Members of our Molecular Cardiology Research Institute volunteered with @communityserv yesterday to prep medically tailored meals for people with heart failure, diabetes, kidney disease and HIV. Proud to support patients beyond the lab. #TuftsMedicine@irisjaffelab
The talk describes a new mechanism discovered in @IrisJaffeLab showing how drugs that treat certain leukemias also cause heart attacks + strokes in cancer survivors. This research sets the stage for new treatments to protect leukemia survivors from CV side effects #AACR25
Congratulations Alec Stepanian on a fantastic presentation. Alec was one of only 10 MD/PhD students across the country chosen to speak at the ASCI/AAP meeting in Chicago. @TuftsMedSchool@TuftsMedicalCtr@hboucher3
Congratulations Alec Stepanian on a fantastic presentation. Alec was one of only 10 MD/PhD students across the country chosen to speak at the ASCI/AAP meeting in Chicago. @TuftsMedSchool @TuftsMedicalCtr @hboucher3
#TuftsMedicine’s @NavinKapur4 presents at #THT2025 on Safety and Efficacy of the preCARDIA System to Mechanically Reduce Cardiac Preload for Acutely Decompensated Heart Failure.
📍 Ensemble A-B | Level 2
⏰ 7:55 – 9:12 am
#Cardiology@IrisJaffeLab
Congratulations Alec Stepanian for a fantastic presentation and for winning the Jonathan Epstein Scholar award at the 227th ICC meeting. @TuftsMedicalCtr @TuftsMedSchool @TuftsMCResearch
Fantastic talk from Alec Stepanian Tufts MD PhD student at AHA Vascular Discovery Conference in Chicago showing his innovative mechanism for arterial thrombosis in cancer patients treated with Ponatinib. @TuftsMedicalCtr @TuftsMedSchool @MTChinMDPhD
Fantastic talk from Alec Stepanian Tufts MD PhD student at AHA Vascular Discovery Conference in Chicago showing his innovative mechanism for arterial thrombosis in cancer patients treated with Ponatinib. @TuftsMedicalCtr @TuftsMedSchool @MTChinMDPhD